TY - JOUR
T1 - Cognitive and affective disorders associated to HIV infection in the HAART era
T2 - Findings from the NeuroICONA study
AU - Starace, F.
AU - Bartoli, L.
AU - Aloisi, M. S.
AU - Antinori, A.
AU - Narciso, P.
AU - Ippolito, G.
AU - Ravasio, L.
AU - Moioli, M. C.
AU - Vangi, D.
AU - Gennero, L.
AU - Coronado, O. V.
AU - Giacometti, A.
AU - Nappa, S.
AU - Perulli, M. L.
AU - Montesarchio, V.
AU - La Gala, A.
AU - Ricci, F.
AU - Cristiano, L.
AU - De Marco, M.
AU - Izzo, C.
AU - Pezzotti, P.
AU - D'Arminio Monforte, A.
PY - 2002
Y1 - 2002
N2 - Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
AB - Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
KW - Cognitive disorder
KW - Depression
KW - HIV infections
KW - Neuropsychological test
UR - http://www.scopus.com/inward/record.url?scp=0036311965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036311965&partnerID=8YFLogxK
U2 - 10.1034/j.1600-0447.2002.02289.x
DO - 10.1034/j.1600-0447.2002.02289.x
M3 - Article
C2 - 12100344
AN - SCOPUS:0036311965
SN - 0001-690X
VL - 106
SP - 20
EP - 26
JO - Acta Psychiatrica Scandinavica
JF - Acta Psychiatrica Scandinavica
IS - 1
ER -